Cetuximab and biomarkers in non-small-cell lung carcinoma

Nitin Patil, Mohammed Abba, Heike AllgayerDepartment of Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg and Molecular Oncology of Solid Tumors Unit, German Cancer Research Center (DKFZ), Heidelberg, GermanyAbstract: Cancer progression is a highly complex process that is driv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patil N, Abba M, Allgayer H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1a1a43be84624441be7288e23a2b1851
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a1a43be84624441be7288e23a2b1851
record_format	dspace
spelling	oai:doaj.org-article:1a1a43be84624441be7288e23a2b18512021-12-02T01:13:10ZCetuximab and biomarkers in non-small-cell lung carcinoma1177-54751177-5491https://doaj.org/article/1a1a43be84624441be7288e23a2b18512012-07-01T00:00:00Zhttp://www.dovepress.com/cetuximab-and-biomarkers-in-non-small-cell-lung-carcinoma-a10388https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Nitin Patil, Mohammed Abba, Heike AllgayerDepartment of Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg and Molecular Oncology of Solid Tumors Unit, German Cancer Research Center (DKFZ), Heidelberg, GermanyAbstract: Cancer progression is a highly complex process that is driven by a constellation of deregulated signaling pathways and key molecular events. In non-small-cell lung cancer (NSCLC), as in several other cancer types, the epidermal growth factor receptor (EGFR) and its downstream signaling components represent a key axis that has been found not only to trigger cancer progression but also to support advanced disease leading to metastasis. Two major therapeutic approaches comprising monoclonal antibodies and small molecule tyrosine kinase inhibitors have so far been used to target this pathway, with a combination of positive, negative, and inconsequential results, as judged by patient survival indices. Since these drugs are expensive and not all patients derive benefits from taking them, it has become both pertinent and paramount to identify biomarkers that can predict not only beneficial response but also resistance. This review focuses on the chimeric monoclonal antibody, cetuximab, its application in the treatment of NSCLC, and the biomarkers that may guide its use in the clinical setting. A special emphasis is placed on the EGFR, including its structural and mechanistic attributes.Keywords: NSCLC, cetuximab, biomarker, cancer progressionPatil NAbba MAllgayer HDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 221-231 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Patil N Abba M Allgayer H Cetuximab and biomarkers in non-small-cell lung carcinoma
description	Nitin Patil, Mohammed Abba, Heike AllgayerDepartment of Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg and Molecular Oncology of Solid Tumors Unit, German Cancer Research Center (DKFZ), Heidelberg, GermanyAbstract: Cancer progression is a highly complex process that is driven by a constellation of deregulated signaling pathways and key molecular events. In non-small-cell lung cancer (NSCLC), as in several other cancer types, the epidermal growth factor receptor (EGFR) and its downstream signaling components represent a key axis that has been found not only to trigger cancer progression but also to support advanced disease leading to metastasis. Two major therapeutic approaches comprising monoclonal antibodies and small molecule tyrosine kinase inhibitors have so far been used to target this pathway, with a combination of positive, negative, and inconsequential results, as judged by patient survival indices. Since these drugs are expensive and not all patients derive benefits from taking them, it has become both pertinent and paramount to identify biomarkers that can predict not only beneficial response but also resistance. This review focuses on the chimeric monoclonal antibody, cetuximab, its application in the treatment of NSCLC, and the biomarkers that may guide its use in the clinical setting. A special emphasis is placed on the EGFR, including its structural and mechanistic attributes.Keywords: NSCLC, cetuximab, biomarker, cancer progression
format	article
author	Patil N Abba M Allgayer H
author_facet	Patil N Abba M Allgayer H
author_sort	Patil N
title	Cetuximab and biomarkers in non-small-cell lung carcinoma
title_short	Cetuximab and biomarkers in non-small-cell lung carcinoma
title_full	Cetuximab and biomarkers in non-small-cell lung carcinoma
title_fullStr	Cetuximab and biomarkers in non-small-cell lung carcinoma
title_full_unstemmed	Cetuximab and biomarkers in non-small-cell lung carcinoma
title_sort	cetuximab and biomarkers in non-small-cell lung carcinoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/1a1a43be84624441be7288e23a2b1851
work_keys_str_mv	AT patiln cetuximabandbiomarkersinnonsmallcelllungcarcinoma AT abbam cetuximabandbiomarkersinnonsmallcelllungcarcinoma AT allgayerh cetuximabandbiomarkersinnonsmallcelllungcarcinoma
_version_	1718403183189950464

Cetuximab and biomarkers in non-small-cell lung carcinoma

Ejemplares similares